Targeted Radiotherapy

3B Pharmaceuticals (3BP) is a leading developer of innovative therapeutic and diagnostic radiopharmaceuticals for oncology applications. The focus of our drug development programs is a theragnostic approach using diagnostic imaging to identify patients who are likely responders to radiopharmaceutical therapy. Furthermore, such radiopharmaceutical precision therapies are designed to effectively target and destroy cancer cells while minimizing damage to healthy tissue.

Using its dedicated technology platform 3BP developed a broad pipeline of novel compounds addressing innovative as well as established drug targets to deliver diagnostic and therapeutic radioisotopes to tumors. In order to optimally develop its diverse pipeline, 3BP has entered into collaborations and license agreements with pharmaceutical industry partners who have a strong commitment to the development of radiopharmaceuticals and complementary capabilities.

The company’s mission is to advance the standard of care in precision oncology through innovative nuclear medicine solutions that address unmet medical needs.